InMed Pharmaceuticals Inc.
INM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 4 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $4.18M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in InMed Pharmaceuticals Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −2 vs. Q2 2022
- Shares held
- 133.2K
- −963.6K (−87.9%) vs. Q2 2022
- Total value
- $876.9K
- +$362.4K (+70.4%) vs. Q2 2022
- New holders
- 5
- 1 more added
- Sold out
- 7
- 9 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 20 | $4.18M |
| Q1 2026 | 9 | $206.0K |
| Q4 2025 | 7 | $240.7K |
| Q3 2025 | 9 | $665.2K |
| Q2 2025 | 7 | $28.5K |
| Q1 2025 | 5 | $13.3K |
| Q4 2024 | 5 | $226.7K |
| Q3 2024 | 15 | $266.0K |
| Q2 2024 | 14 | $116.6K |
| Q1 2024 | 18 | $249.2K |
| Q4 2023 | 17 | $334.4K |
| Q3 2023 | 10 | $18.6K |
| Q2 2023 | 10 | $14.5K |
| Q1 2023 | 15 | $109.4K |
| Q4 2022 | 14 | $234.4K |
| Q3 2022 | 15 | $876.9K |
| Q2 2022 | 18 | $514.5K |
| Q1 2022 | 19 | $341.9K |
| Q4 2021 | 18 | $536.4K |
| Q3 2021 | 19 | $979.9K |
| Q2 2021 | 20 | $2.99M |
| Q1 2021 | 22 | $1.55M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding InMed Pharmaceuticals Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 90,000 | $593.0K | 0.01% | −866,118−90.6% | Reduced |
| Sabby Management, LLC | 15,284 | $101.0K | 0.22% | +15,284 | New |
| Millennium Management LLC | 13,922 | $91.0K | 0.00% | +13,922 | New |
| Bank of America Corp | 6,770 | $45.0K | 0.00% | +6,770 | New |
| UBS Group AG | 5,797 | $38.0K | 0.00% | +5,797 | New |
| Tower Research Capital LLC (TRC) | 1,067 | $7.00K | 0.00% | +1,067 | New |
| Morgan Stanley | 134 | $1.00K | 0.00% | +117+688.2% | Added |
| TD Waterhouse Canada Inc. | 85 | $757 | 0.00% | −2,045−96.0% | Reduced |
| Federation des caisses Desjardins du Quebec | 19 | $125 | 0.00% | −492−96.3% | Reduced |
| National Bank of Canada | 7 | $0 | 0.00% | −189−96.4% | Reduced |
| Royal Bank of Canada | 9 | $0 | 0.00% | −241−96.4% | Reduced |
| TCI Wealth Advisors, Inc. | 5 | $0 | 0.00% | −120−96.0% | Reduced |
| AllSquare Wealth Management LLC | 21 | $0 | 0.00% | −524−96.1% | Reduced |
| Advisor Group Holdings, Inc. | 76 | $0 | 0.00% | −1,109−93.6% | Reduced |
| Gables Capital Management Inc. | 1 | $0 | 0.00% | −29−96.7% | Reduced |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −49,700−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −48,281−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −13,905−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −12,966−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −10,832−100.0% | Sold out |
| Toronto Dominion Bank | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Banque Cantonale Vaudoise | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| HC Financial Advisors Inc | – | – | – | – | Not filed |